PE20040724A1 - Composicion para la administracion oral de calcitonina - Google Patents
Composicion para la administracion oral de calcitoninaInfo
- Publication number
- PE20040724A1 PE20040724A1 PE2003000747A PE2003000747A PE20040724A1 PE 20040724 A1 PE20040724 A1 PE 20040724A1 PE 2003000747 A PE2003000747 A PE 2003000747A PE 2003000747 A PE2003000747 A PE 2003000747A PE 20040724 A1 PE20040724 A1 PE 20040724A1
- Authority
- PE
- Peru
- Prior art keywords
- calcitonin
- composition
- oral administration
- refers
- amount
- Prior art date
Links
- 102000055006 Calcitonin Human genes 0.000 title abstract 4
- 108060001064 Calcitonin Proteins 0.000 title abstract 4
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 title abstract 4
- 229960004015 calcitonin Drugs 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 abstract 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960002446 octanoic acid Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA DE ADMINISTRACION ORAL QUE COMPRENDE: a) UNA SAL DISODICA DEL ACIDO N-(5-CLOROSALICILOIL)-8-AMINOCAPRILICO, ACIDO N-(8-[2-HIDROXIBENZOIL]AMINO]CAPRILICO O ACIDO N-(10-[2-HIDROXIBENZOIL]AMINODECANOICO; b) DE 0.1 A 2.5 MILIGRAMOS DE CALCITONINA DE TAL FORMA QUE LA CANTIDAD DE ACIDO LIBRE A LA CANTIDAD DE CALCITONINA, ESTA EN EL RANGO DE 10 A 250:1 EN PESO. SE REFIERE TAMBIEN A UN METODO DE TRATAMIENTO EN EL CUAL SE ADMINISTRA DICHA COMPOSICION A UN HUESPED HUMANO 5 A 30 MINUTOS ANTES DE UN ALIMENTO, SIENDO UTILES EN EL TRATAMIENTO DE DESORDENES QUE RESPONDEN A LA ACCION DE CALCITONINA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40013902P | 2002-08-01 | 2002-08-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040724A1 true PE20040724A1 (es) | 2004-12-06 |
Family
ID=31495795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000747A PE20040724A1 (es) | 2002-08-01 | 2003-07-30 | Composicion para la administracion oral de calcitonina |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20060135402A1 (es) |
| EP (1) | EP1526871A1 (es) |
| JP (4) | JP2005535689A (es) |
| KR (6) | KR20170097232A (es) |
| CN (1) | CN1671418A (es) |
| AR (1) | AR040737A1 (es) |
| AU (1) | AU2003260346B2 (es) |
| BR (1) | BR0313177A (es) |
| CA (1) | CA2494212A1 (es) |
| IL (1) | IL166337A (es) |
| MX (1) | MXPA05001266A (es) |
| NO (1) | NO20051023L (es) |
| NZ (1) | NZ537944A (es) |
| PE (1) | PE20040724A1 (es) |
| PL (1) | PL373143A1 (es) |
| RU (1) | RU2355417C2 (es) |
| TW (1) | TWI307279B (es) |
| WO (1) | WO2004012772A1 (es) |
| ZA (1) | ZA200500516B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080049128A (ko) * | 2005-09-19 | 2008-06-03 | 에미스페어 테크놀로지스, 인코포레이티드 | Ｎ-(5-클로로살리실로일)-8-아미노카프릴산 이나트륨염의결정형 |
| GB0522566D0 (en) | 2005-11-04 | 2005-12-14 | Novartis Ag | Organic compounds |
| WO2008109385A2 (en) * | 2007-03-02 | 2008-09-12 | Novartis Ag | Oral administration of a calcitonin |
| EP2460515B1 (en) * | 2007-08-09 | 2017-03-08 | Novartis AG | Oral calcitonin compositions and applications thereof |
| US8022048B2 (en) | 2007-11-02 | 2011-09-20 | Emisphere Technologies, Inc. | Method of treating vitamin B12 deficiency |
| WO2011017346A2 (en) * | 2009-08-03 | 2011-02-10 | Emisphere Technologies, Inc. | Fast-acting naproxen composition with reduced gastrointestinal effects |
| WO2012130193A1 (en) | 2011-03-31 | 2012-10-04 | Zentiva, K.S. | Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration |
| CN104095828A (zh) * | 2014-07-29 | 2014-10-15 | 中国药科大学 | 一种降钙素口服肠溶组合物及其制备方法 |
| EP3256149A4 (en) * | 2015-02-09 | 2019-08-14 | Entera Bio Ltd. | FORMULATION FOR ORAL ADMINISTRATION OF ACTIVE SUBSTANCES |
| CN104961687B (zh) * | 2015-06-03 | 2017-07-25 | 苏州维泰生物技术有限公司 | 1,2‑二嗪衍生物及其制剂、用途 |
| AU2017311698B2 (en) | 2016-08-17 | 2024-09-05 | Entera Bio Ltd. | Formulations for oral administration of active agents |
| CR20230308A (es) | 2020-12-11 | 2023-09-08 | Civi Biopharma Inc | Entrega oral de conjugados antisentido que tienen por blanco a pcsk9 |
| BR112023021766A2 (pt) | 2021-04-22 | 2024-01-23 | Civi Biopharma Inc | Dispensação oral de oligonucleotídeo |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5629020A (en) * | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
| JP4588221B2 (ja) * | 1999-04-05 | 2010-11-24 | エミスフェアー・テクノロジーズ・インク | 活性剤を送達するための二ナトリウム塩、一水和物、およびエタノール溶媒和物 |
| WO2000059480A1 (en) * | 1999-04-05 | 2000-10-12 | Emisphere Technologies, Inc. | Lyophilized solid dosage forms and methods of making |
| US7049283B2 (en) * | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
-
2003
- 2003-07-30 AR AR20030102740A patent/AR040737A1/es unknown
- 2003-07-30 PE PE2003000747A patent/PE20040724A1/es not_active Application Discontinuation
- 2003-07-30 TW TW092120855A patent/TWI307279B/zh not_active IP Right Cessation
- 2003-07-31 PL PL03373143A patent/PL373143A1/xx unknown
- 2003-07-31 CN CNA038182955A patent/CN1671418A/zh active Pending
- 2003-07-31 US US10/523,421 patent/US20060135402A1/en not_active Abandoned
- 2003-07-31 BR BR0313177-7A patent/BR0313177A/pt not_active Application Discontinuation
- 2003-07-31 KR KR1020177022695A patent/KR20170097232A/ko not_active Ceased
- 2003-07-31 EP EP03766387A patent/EP1526871A1/en not_active Ceased
- 2003-07-31 KR KR1020057001733A patent/KR20050032101A/ko not_active Ceased
- 2003-07-31 WO PCT/EP2003/008498 patent/WO2004012772A1/en not_active Ceased
- 2003-07-31 KR KR1020127031292A patent/KR20130004389A/ko not_active Ceased
- 2003-07-31 CA CA002494212A patent/CA2494212A1/en not_active Abandoned
- 2003-07-31 KR KR1020107029690A patent/KR20110014690A/ko not_active Ceased
- 2003-07-31 RU RU2005105691/15A patent/RU2355417C2/ru not_active IP Right Cessation
- 2003-07-31 KR KR1020147016376A patent/KR20140084354A/ko not_active Ceased
- 2003-07-31 KR KR1020167025673A patent/KR20160113319A/ko not_active Ceased
- 2003-07-31 AU AU2003260346A patent/AU2003260346B2/en not_active Ceased
- 2003-07-31 JP JP2004525407A patent/JP2005535689A/ja not_active Withdrawn
- 2003-07-31 NZ NZ537944A patent/NZ537944A/en not_active IP Right Cessation
- 2003-07-31 MX MXPA05001266A patent/MXPA05001266A/es unknown
-
2005
- 2005-01-17 IL IL166337A patent/IL166337A/en active IP Right Grant
- 2005-01-19 ZA ZA200500516A patent/ZA200500516B/xx unknown
- 2005-02-25 NO NO20051023A patent/NO20051023L/no unknown
-
2007
- 2007-05-24 US US11/805,748 patent/US7569539B2/en not_active Expired - Fee Related
-
2010
- 2010-11-08 JP JP2010249363A patent/JP2011026348A/ja active Pending
-
2013
- 2013-12-02 JP JP2013249349A patent/JP5941035B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-07 JP JP2016001745A patent/JP2016056190A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160113319A (ko) | 2016-09-28 |
| US7569539B2 (en) | 2009-08-04 |
| AU2003260346A1 (en) | 2004-02-23 |
| KR20110014690A (ko) | 2011-02-11 |
| EP1526871A1 (en) | 2005-05-04 |
| BR0313177A (pt) | 2005-06-14 |
| IL166337A (en) | 2011-10-31 |
| KR20170097232A (ko) | 2017-08-25 |
| IL166337A0 (en) | 2006-01-16 |
| JP5941035B2 (ja) | 2016-06-29 |
| RU2005105691A (ru) | 2006-01-20 |
| US20070232524A1 (en) | 2007-10-04 |
| CN1671418A (zh) | 2005-09-21 |
| KR20140084354A (ko) | 2014-07-04 |
| JP2005535689A (ja) | 2005-11-24 |
| JP2014062112A (ja) | 2014-04-10 |
| NO20051023L (no) | 2005-04-27 |
| AR040737A1 (es) | 2005-04-20 |
| PL373143A1 (en) | 2005-08-22 |
| JP2016056190A (ja) | 2016-04-21 |
| RU2355417C2 (ru) | 2009-05-20 |
| WO2004012772A1 (en) | 2004-02-12 |
| TW200408409A (en) | 2004-06-01 |
| TWI307279B (en) | 2009-03-11 |
| NZ537944A (en) | 2006-11-30 |
| KR20050032101A (ko) | 2005-04-06 |
| US20060135402A1 (en) | 2006-06-22 |
| MXPA05001266A (es) | 2005-04-28 |
| JP2011026348A (ja) | 2011-02-10 |
| CA2494212A1 (en) | 2004-02-12 |
| ZA200500516B (en) | 2006-07-26 |
| AU2003260346B2 (en) | 2007-12-13 |
| KR20130004389A (ko) | 2013-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20040724A1 (es) | Composicion para la administracion oral de calcitonina | |
| UY29759A1 (es) | Formulaciones de ibandronato mejoradas | |
| NO20076219L (no) | Farmasoytisk formulering med apomorfin for bukkal administrering | |
| EE200200245A (et) | Farmatseutiline kompositsioon, mis sisaldab tolterodiini ja selle kasutamine | |
| AR035927A1 (es) | Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr | |
| RU2013150659A (ru) | Пероральное введение кальцитонина | |
| IS8485A (is) | Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki | |
| BR0008509A (pt) | Composição farmacêutica oral estabilizada contendo iodeto e iodato e método | |
| TR200101633T2 (tr) | Farmasötik bileşim | |
| EP1571155A4 (en) | PEPTIDES AND MEDICAL COMPOSITIONS WITH THE SAME | |
| ATE410152T1 (de) | Therapeutisches system mit amoxicillin und clavulansäure | |
| RU2007104774A (ru) | Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы | |
| PE20040670A1 (es) | Nuevas composiciones farmaceuticas que contienen ambroxol y yoduro de isopropamida | |
| BR0109279A (pt) | Antagonistas de lhrh, sua preparação e aplicação como medicamento | |
| AR036591A1 (es) | Uso de la hl en hiperestimulacion ovarica controlada | |
| ATE295845T1 (de) | Prucaloprid-n-oxid | |
| AR048068A1 (es) | Piperazinas derivadas de urea para el tratamiento de endometriosis | |
| PE20030732A1 (es) | Empleo de alquilfosfocolinas en el tratamiento preventivo de enfermedades causadas por protozoarios | |
| EP1730174A4 (en) | PEPTIDE CARRIER FOR THE ADMINISTRATION OF MEDICINAL PRODUCTS | |
| CO2020001742A2 (es) | Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil | |
| SG146631A1 (en) | Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep | |
| EA200501765A3 (ru) | Средство для лечения болезней суставов | |
| DK2058328T3 (da) | Derivater af biologisk aktivt peptid VAPEEHPTLLTEAPLNPK | |
| BR0314525A (pt) | Composições e métodos para tratamento de disfunção sexual | |
| DE602006009511D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von Hauterkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |